References

• Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–172.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19–28.
   PubMed Web of Science ®Google Scholar
• Nicassio PM, Weisman MH, Schuman C, Young CW. The role of generalized pain and pain behavior in tender point scores in fibromyalgia. J Rheumatol. 2000;27:1056–1062.
   PubMed Web of Science ®Google Scholar
• McBeth J, Silman AJ. The role of psychiatric disorders in fibromyalgia. Curr Rheumatol Rep 2001;3:157–164.
   PubMedGoogle Scholar
• Ahles TA, Khan SA, Yunus MB, Spiegell DA, Masi AT. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry 1991;148:1721–1726.
   PubMed Web of Science ®Google Scholar
• Hudson JL, Goldenberg DL, Pope Jr HG, Keck Jr PK, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992; 92; 363–367.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104–113.
   PubMed Web of Science ®Google Scholar
• Versiani M, Ontiveros A, Mazzotti G, Ospina J, Dávila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M. Fluoxetine versus amitryptiline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharmacol. 1999;14:321–327.
   Web of Science ®Google Scholar
• Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the Treatment of Fibromyalgia Symptoms. Journal of Pain and Symptom Management 2001; 22; 2: 704–708.
   Google Scholar
• Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitryptiline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48:252–263.
   PubMed Web of Science ®Google Scholar
• Moret C, Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treat. 2006;2:537–548.
   Google Scholar
• Ardid D, Guilbaud G. Antinociceptive effects of acute and ‘chronic’ injections of tricyclic antidepressant drugs in a new model of mononeuropathy in rats. Pain. 1992;49:279–287.
   PubMed Web of Science ®Google Scholar
• Esser MJ, Sawynok J. Acute amitryptylline in a rat model of neuropathic pain: differential symptom and route effects. Pain. 1999;80:643–653.
   PubMed Web of Science ®Google Scholar
• Sawynok J, Esser MJ, Reid AR. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999;82:149–158.
   PubMed Web of Science ®Google Scholar
• O'Malley PG, Balden E, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of fibromyalgia with antidepressants: A meta-analysis. J Gen Intern Med. 2000; 15:659–666.
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Mayskiy M, Mossey C, Ruthazer R, Schmid CH A randomized, double- blind crossover trial of fluoxetine and amitryptiline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852–1859.
   PubMed Web of Science ®Google Scholar
• Nørregaard J, Volkmann H, Danneskiold-Samsø B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445–449.
   PubMed Web of Science ®Google Scholar
• Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;37:1561–1565.
   PubMed Web of Science ®Google Scholar
• Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitryptiline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279–1286.
   PubMedGoogle Scholar
• Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Hum Psychopharmacol. 2006;21:337–345.
   Web of Science ®Google Scholar
• Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics. 2005;46:379–384.
   PubMed Web of Science ®Google Scholar
• Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain. 2005;9:33–38.
   Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for the DSM-IV Axis I Disorders—patient edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1995.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW: DSM-IV Eksen IBozukluklari Icin Yapilandirilmis Klinik Gorusme. [Translated by A Corapcioglu]. Ankara: Hekimler Yayin Birligi, 1995.
   Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728–733.
   PubMed Web of Science ®Google Scholar
• Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9–12.
   PubMed Web of Science ®Google Scholar
• Beck AT, Waed CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
   PubMed Web of Science ®Google Scholar
• Hisli N. The reliability and validity study of the Beck Depression Inventory in a Turkish sample. Turkish. Psikoloji Dergisi 1988;6:118–122. (in Turkish)
   Google Scholar
• Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893–897.
   PubMed Web of Science ®Google Scholar
• Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cognitive Psychother 1998;12:163–172.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety disorders by rating. Br J Med Psychol 1959;32:50–65.
   PubMed Web of Science ®Google Scholar
• Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolac P. [Hamilton anxiety scale, inter-rater reliability and validity study] Turkish. Turk Psikiyatri Dergisi 1998;9:114–117.
   Google Scholar
• Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001;42:161–165.
   PubMed Web of Science ®Google Scholar
• Hujkisson HC. Visual analog scales. In: Handbook of psychiatric measures. Washington, DC: American Psychiatric Press, 2000:601–603.
   Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Suppl 1987;76:1–100.
   Google Scholar
• SPSS for Windows, Version 11.01, Chicago, IL, 2001, customer ID number 114094.
   Google Scholar
• Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66:837–844.
   PubMed Web of Science ®Google Scholar
• Hakimi R. Is fibromyalgia a disease? Regarding the contribution in DMW 23/2004 Dtsch Med Wochenschr 2005; 130:1278–1279.
   Google Scholar
• Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32:305–316.
   PubMed Web of Science ®Google Scholar
• Bergman S. Management of musculoskeletal pain Best Pract Res Clin Rheumatol 2007;21:153–166.
   Google Scholar
• Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389–400.
   PubMed Web of Science ®Google Scholar
• Dryson E. Venlafaxine and fibromyalgia. N Z Med J, 2000. 113:87.
   Web of Science ®Google Scholar
• Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14–17.
   PubMed Web of Science ®Google Scholar
• Zijlstra TR, Barendregt EJ, van de Laar MA. 2002. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 46(suppl 9):S105.
   Google Scholar
• Sayar K, Aksu G, Ak I, et al. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37:1561–1565.
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Int J Psychiatry Clin Pract 2004; 8:47–51.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5–15.
   PubMed Web of Science ®Google Scholar
• Leo RJ, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 2006;7:637–642.
   Google Scholar
• Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576–584.
   PubMed Web of Science ®Google Scholar
• Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A doubleblind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19 Suppl 1:S27–S35.
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63:610–615.
   PubMed Web of Science ®Google Scholar
• Fassbender K, Samborsky W, Kellner M, Müller W, Lautenbacher S. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol 1997;16:76–79.
   PubMed Web of Science ®Google Scholar